Pharsight

1. Bylvay patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7132416	ALBIREO	Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia	Sep, 2022 (1 year, 23 days ago)
US10975046	ALBIREO	Crystal modifications of odevixibat	Jun, 2039 (15 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10093697	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (8 years from now)
US10981952	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (8 years from now)
US9694018	ALBIREO	IBAT inhibitors for the treatment of liver disease	Nov, 2031 (8 years from now)
US10011633	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (8 years from now)
US10487111	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (8 years from now)
US11365182	ALBIREO	Crystal modifications of odevixibat	Jun, 2039 (15 years from now)
US11583539	ALBIREO	Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors	Nov, 2041 (18 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 20, 2026
Orphan Drug Exclusivity (ODE)	Jul 20, 2028
New Indication (I)	Jun 13, 2026

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: 2025-07-20

Market Authorisation Date: 20 July, 2021

Treatment: Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of reducing serum bile acids in patients 3 months or older sufferi...

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL